Loading... Loading... On CNBC's “Mad Money Lightning Round,” Jim Cramer said Recursion Pharmaceuticals, Inc. RXRX is a “terrific spec” and he recommended buying the same. On May 9, Recursion Pharmaceuticals reported better-than-expected first-quarter financial results. Corning Incorporated GLW has “not been able to generate the kind of return that I've wanted,” Cramer said. “I would not be a buyer all the way up here.” See Also: Jim Cramer Says This Industrial Stock Is Doing ‘Very Well’; Here’s His Take On ...